Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV16 E7 peptide-pulsed autologous dendritic cells (National Taiwan University Hospital)
- Development stage
- Unknown
- Lead developer
- National Taiwan University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intralymphatic
01
Overview
HPV16 E7 peptide-pulsed autologous dendritic cells is an experimental cellular immunotherapy developed by National Taiwan University Hospital for the treatment of recurrent cervical cancer. The therapeutic process involves isolating a patient's peripheral blood mononuclear cells (PBMCs) and differentiating them into dendritic cells (DCs) in vitro using cytokines such as GM-CSF and IL-4. These autologous DCs are then pulsed with synthetic peptides representing cytotoxic T lymphocyte (CTL) epitopes of the Human Papillomavirus (HPV) Type 16 E7 oncoprotein. Once administered via intralymphatic injection into the inguinal lymph nodes, these mature, antigen-loaded DCs are designed to prime and activate the patient's immune system to mount a targeted T-cell response against HPV16-positive malignant cells.
- Other names
- HPV16 E7-pulsed DCsHPV-16 E7-pulsed DCsHPV 16 E7-pulsed DCsAutologous dendritic cells pulsed with HPV Type 16 E7 antigenHPV16 E7 peptide-pulsed autologous DCsHPV-16 E7 peptide-pulsed autologous DCsHPV 16 E7 peptide-pulsed autologous DCs
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on HPV16 E7 peptide-pulsed autologous dendritic cells (National Taiwan University Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV16 E7 peptide-pulsed autologous dendritic cells (National Taiwan University Hospital).